Pharmacologic control of oxidative stress and inflammation determines whether diabetic glomerulosclerosis progresses or decreases: A pilot study in sclerosis-prone mice - Fig 1
- Fabrizio Grosjean (352916)
- Elena M. Yubero-Serrano (141587)
- Feng Zheng (91182)
- Vittoria Esposito (5787344)
- Shobha Swamy (5787347)
- Sharon J. Elliot (3153597)
- Weijing Cai (327350)
- Helen Vlassara (276722)
- Fadi Salem (3176307)
- Gary E. Striker (413610)
Publication date
September 2018
DOI Publisher
Public Library of Science (PLoS)Abstract
A) Albumin to creatinine ratio (ACR) at sacrifice (22 weeks). B) ACR follow-up for 22 weeks. C) Periodic acid–Schiff (PAS) staining: a) non-DB, b) DB, c) DB EN, d) DB PYR+EN, e) DB PPS+EN, f) DB PPS+PYR+EN. D) Morphometric evaluation of glomerular PAS positive areas. E) Kidney TGFβ1 mRNA levels. *ppp#p<0.001. DB, diabetics; EN, enalapril; PPS, pentosan polysulfate; PYR, pyridoxamine; PAS, periodic acid–Schiff; TGFβ1, transforming growth factor β1.</p
Add to ORKG